Status:
ACTIVE_NOT_RECRUITING
A Targeted Amino Acid Supplement for People With Parkinson's Disease
Lead Sponsor:
UConn Health
Conditions:
Parkinson Disease, Idiopathic
Eligibility:
All Genders
55+ years
Phase:
EARLY_PHASE1
Brief Summary
The goal of this clinical trial is to learn if an amino acid supplement that is specifically made for people with Parkinson disease can improve nutrition without interfering with dopamine medication i...
Detailed Description
This is a prospective, double-blind, randomized control trial with a repeated measures design. After being screened via phone screens and completing an initial visit that includes additional in person...
Eligibility Criteria
Inclusion
- diagnosis of idiopathic Parkinson disease by patient report
- 55 years or older
- Has been using dopamine replacement medication (e.g. levodopa) for at least 2 years.
- On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months.
Exclusion
- Apparent cognitive impairment as determined by phone screening (TICS)
- Diagnosis of Parkinsonism or atypical Parkinson's Disease
- Are prescribed a dopamine antagonist
- Any unstable medical condition
- Any known bleeding disorder or currently taking blood thinners
- Using deep brain stimulation
- Gastric or bowel resection surgery
Key Trial Info
Start Date :
May 22 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06954662
Start Date
May 22 2025
End Date
September 1 2025
Last Update
July 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UConn Health, Clinical Research Center
Farmington, Connecticut, United States, 06030-3805